Work

Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?

Year: 2020

Type: article

Abstract: Chimeric antigen receptor (CAR) T cell therapy provides hope for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Two different autologous CD19-directed CAR T cell therapy products, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel, have been approved for use by the US Food and Drug Administration and European Medicines Administration for the treatment of DLBCL after 2 or more previous lines of therapy, and a third approval for DLBCL and a separate product for mantle cell lymphoma are anticipated in the coming months [1-4].

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2020.07.009

Author: Frederick L. Locke

Institution: Moffitt Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650